FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Silvano Brienza

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
Thierry Delozier; Jean-Paul Guastalla; Alejandro Yovine; Christelle Levy; Philippe Chollet; Mireille Mousseau; Rémi Delva; David Coeffic; Jean-Michel Vannetzel; Eliette-Sudriez Zazzi; Silvano Brienza; Esteban Cvitkovic
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Thierry Petit; Abdellatif Benider; Alejandro Yovine; Philippe Bougnoux; Dominique Spaeth; Frédérique Maindrault-Goebel; Daniel Serin; Jean-Dominique Tigaud; Jean-Christophe Eymard; Hélène Simon; Brigitte Bertaux; Silvano Brienza; Esteban Cvitkovic
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer.
Michèle Boisdron-Celle; C Craipeau; Silvano Brienza; Rémi Delva; Véronique Guérin-Meyer; Esteban Cvitkovic; Erick Gamelin
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Silvano Brienza (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Thierry Delozier; Jean-Paul Guastalla; Alejandro Yovine; Christelle Levy; Philippe Chollet; Mireille Mousseau; Rémi Delva; David Coeffic; Jean-Michel Vannetzel; Eliette-Sudriez Zazzi; Silvano Brienza; Esteban Cvitkovic
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Anti-cancer drugs 2006;17(9):1067-73.
2006: Thierry Petit; Abdellatif Benider; Alejandro Yovine; Philippe Bougnoux; Dominique Spaeth; Frédérique Maindrault-Goebel; Daniel Serin; Jean-Dominique Tigaud; Jean-Christophe Eymard; Hélène Simon; Brigitte Bertaux; Silvano Brienza; Esteban Cvitkovic
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer.
Anti-cancer drugs 2006;17(3):337-43.
2002: Michèle Boisdron-Celle; C Craipeau; Silvano Brienza; Rémi Delva; Véronique Guérin-Meyer; Esteban Cvitkovic; Erick Gamelin
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Cancer chemotherapy and pharmacology 2002;49(3):235-43.
2001: MA Bensmaïne; Michel Marty; A de Gramont; Silvano Brienza; Francis Lévi; M Ducreux; Eric François; Erick Gamelin; Harry Bleiberg; Esteban Cvitkovic
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
British journal of cancer 2001;85(4):509-17.
2001: Carlo Garufi; Cecilia Nisticò; Silvano Brienza; Angela Vaccaro; Anna Maria D'Ottavio; Albina Rita Zappalà; Anna Maria Aschelter; Edmondo Terzoli
Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(2):179-82.
2000: A de Gramont; Silvano Brienza; Michel Marty; Francis Lévi; M Ducreux; Eric François; Erick Gamelin; Harry Bleiberg; P Bleuzen; J Simon; Esteban Cvitkovic
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2335-43.
2000: Carlo Garufi; Silvano Brienza; Patrizia Pugliese; Anna Maria Aschelter; F Bertheault-Cvitkovic; Cecilia Nisticò; Salvatore Giunta; Mauro Caterino; Diana Giannarelli; Maurizio Cosimelli; Francis Lévi; Edmondo Terzoli
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
Anti-cancer drugs 2000;11(6):495-501.
2000: Carlo Garufi; Stefania Vaglio; Silvano Brienza; L Conti; RM D'Attino; Gabriella Girelli; Edmondo Terzoli
Immunohemolytic anemia following oxaliplatin administration.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):497.
2000: Martin A Graham; Graham F Lockwood; Dennis Greenslade; Silvano Brienza; M Bayssas; Erick Gamelin
Clinical pharmacokinetics of oxaliplatin: a critical review.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1205-18.
2000: C Massari; Silvano Brienza; M Rotarski; J Gastiaburu; Jean-Louis Misset; D Cupissol; E Alafaci; H Dutertre-Catella; G Bastian
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Cancer chemotherapy and pharmacology 2000;45(2):157-64.
1999: Silvano Brienza; MA Bensmaïne; Patrick Soulié; C Louvet; Erick Gamelin; Eric François; M Ducreux; Michel Marty; Thierry André; F de Braud; Harry Bleiberg; V Ségal; M Itzhaki; Esteban Cvitkovic
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1311-6.
1999: Francis Lévi; R Zidani; Silvano Brienza; L Dogliotti; B Perpoint; M Rotarski; Y Letourneau; J F Llory; Philippe Chollet; A Le Rol; Christian Focan
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Cancer 1999;85(12):2532-40.
1999: Sylvie Giacchetti; M Itzhaki; G Gruia; René Adam; R Zidani; Francis Kunstlinger; Silvano Brienza; E Alafaci; F Bertheault-Cvitkovic; Claude Jasmin; M Reynes; Henri Bismuth; Jean-Louis Misset; Francis Lévi
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):663-9.
1999: N Germann; Silvano Brienza; M Rotarski; Jean-François Emile; Mario Di Palma; M Musset; M Reynes; Patrick Soulié; Esteban Cvitkovic; Jean-Louis Misset
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):351-4.
1998: I Monnet; Silvano Brienza; F Hugret; S Voisin; J Gastiaburu; JC Saltiel; Patrick Soulié; Jean-Pierre Armand; Esteban Cvitkovic; H de Cremoux
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1124-7.
1998: Béatrice Gerard; Harry Bleiberg; D Van Daele; Thierry Gil; Alain Hendlisz; A Di Leo; B Fernez; Silvano Brienza
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Anti-cancer drugs 1998;9(4):301-5.
1998: Jean-Marc Extra; Michel Marty; Silvano Brienza; Jean-Louis Misset
Pharmacokinetics and safety profile of oxaliplatin.
Seminars in oncology 1998;25(2 Suppl 5):13-22.
1998: Erick Gamelin; Michèle Boisdron-Celle; A Lebouil; Alain Turcant; A Cailleux; A Krikorian; Silvano Brienza; Esteban Cvitkovic; F Larra; J Robert; P Allain
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters.
Anti-cancer drugs 1998;9(3):223-8.
1997: Erick Gamelin; A L Bouil; Michèle Boisdron-Celle; Alain Turcant; Rémi Delva; A Cailleux; A Krikorian; Silvano Brienza; Esteban Cvitkovic; J Robert; F Larra; P Allain
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):891-9.
1997: Patrick Soulié; E Raymond; Silvano Brienza; Esteban Cvitkovic
[Oxaliplatin: the first DACH platinum in clinical practice].
Bulletin du cancer 1997;84(6):665-73.
1996: Philippe Chollet; MA Bensmaïne; Silvano Brienza; C Deloche; Hervé Curé; H Caillet; Esteban Cvitkovic
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(10):1065-70.
1996: F Bertheault-Cvitkovic; A Jami; M Ithzaki; P D Brummer; Silvano Brienza; R Adam; F Kunstlinger; H Bismuth; Jean-Louis Misset; Francis Lévi
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):2950-8.
1996: D Machover; Eduardo Diaz-Rubio; A de Gramont; A Schilf; J J Gastiaburu; Silvano Brienza; M Itzhaki; G Metzger; D N'Daw; J Vignoud; Albert Abad; E Francois; Erick Gamelin; Michel Marty; Javier Sastre; Jean-François Seitz; Marc Ychou
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):95-8.
1995: P Deprés-Brummer; F Berthault-Cvitkovic; F Lĕvi; Silvano Brienza; J M Vannetzel; Claude Jasmin; Jean-Louis Misset
Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
The Journal of infusional chemotherapy 1995;5(3 Suppl 1):144-7.
1994: G Metzger; C Massari; M C Etienne; M Comisso; Silvano Brienza; Y Touitou; G Milano; G Bastian; Jean-Louis Misset; Francis Lévi
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Clinical pharmacology and therapeutics 1994;56(2):190-201.
1993: F Levi; B Perpoint; Carlo Garufi; Christian Focan; Philippe Chollet; P Depres-Brummer; R Zidani; Silvano Brienza; M Itzhaki; S Iacobelli
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.
European journal of cancer (Oxford, England : 1990) 1993;29A(9):1280-4.
1993: F Bertheault-Cvitkovic; Francis Lévi; S Soussan; Silvano Brienza; R Adam; M Itzhaki; Jean-Louis Misset; H Bismuth
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 1993;29A(13):1851-4.
1993: Francis Lévi; Silvano Brienza; G Metzer; P Deprés-Brummer; F Bertheault-Cvitkovic; R Zidani; R Adam; Jean-Louis Misset
Implications of chronobiology for 5-fluorouracil (5-FU) efficacy.
Advances in experimental medicine and biology 1993;339():169-83.
1992: Francis Lévi; Jean-Louis Misset; Silvano Brienza; R Adam; G Metzger; M Itzakhi; J P Caussanel; F Kunstlinger; S Lecouturier; A Descorps-Declère
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Cancer 1992;69(4):893-900.
1992: G Mathé; P Meyer; Silvano Brienza; M Gil-Delgado; Simone Orbach-Arbouys; M Itzhaki
Retrospective study correlating clinical infectious history and peripheral blood T-cell subpopulations in cancer, GvH and HIV+ patients.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1992;46(1):17-9.
1990: J P Caussanel; Francis Lévi; Silvano Brienza; Jean-Louis Misset; M Itzhaki; R Adam; G Milano; B Hecquet; G Mathé
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
Journal of the National Cancer Institute 1990;82(12):1046-50.
1989: G Mathé; Yoko Kidani; M Segiguchi; Masazumi Eriguchi; G Fredj; G Peytavin; Jean-Louis Misset; Silvano Brienza; F de Vassals; E Chenu
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1989;43(4):237-50.
1987: G Mathé; M D Lopez; M Fréchet; F de Vassal; Silvano Brienza; J Gastiaburu
A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1987;41(1):13-26.
1986: G Mathé; H Umezawa; S Oka; Jean-Louis Misset; Silvano Brienza; F de Vassal; M Musset; P Ribaud; Haim Tapiero
An oriented phase II trial of THP-adriamycin in breast carcinoma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):376-9.
1986: G Mathé; Yoko Kidani; K Triana; Silvano Brienza; P Ribaud; E Goldschmidt; E Ecstein; R Despax; M Musset; Jean-Louis Misset
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):372-6.
1986: G Mathé; H Umezawa; Jean-Louis Misset; Silvano Brienza; C Canon; M Musset; P Reizenstein
Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1986;40(10):379-82.